Case Western Reserve University Receives $5M for the Center for Stem Cell and Regenerative Medicine
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 3 minutes
The Center for Stem Cell & Regenerative Medicine (CSCRM), comprised of Case Western Reserve University, Cleveland Clinic (CC), University Hospitals (UH), and Athersys, Inc. has received $5 million from Ohio's Third Frontier Commission under the Research Commercialization Program.
The funding will help support new stem cell technologies including two commercial, four emerging and three pilot projects. This funding will be matched by each of the projects to create a $10 million grant benefiting stem cell and regenerative medicine in Ohio.
"This funding provides CSCRM the support it needs to continue to aggressively move new technologies from academic labs towards commercial development," said Stan Gerson, director of the Center for Stem Cell & Regenerative Medicine. "We have linked corporate partners to our major projects and have been gratified by the development of a stem cell biotechnology commercial landscape in our region. Our goal is to rapidly move stem cell research from the lab to patients through clinical trials, using our strong background in preclinical models."
The continued research efforts will result in efficient clinical applications and commercialization of stem cells to benefit patients throughout Ohio. To date, such efforts have brought in $170 million in new commercial development and investment in Ohio.
"This grant continues to build distinctive and broad reach capabilities that are making Ohio a leader in the development and clinical use of cellular therapies," said Baiju R. Shah, President and CEO of BioEnterprise. "Ohioans benefit both through the resulting company development and jobs as well as by having access to leading-edge clinical therapies at our region's clinical institutions."
The use of stem cells has focused on leukemia and myeloma treatments with recent applications in cardiovascular disease. Current healthcare is limited to the use of drugs or devices to treat disease and injury. CSCRM, located in Northeast Ohio but collaborating state wide, is positioned to implement new stem cell technologies in the commercial and therapeutic arenas.
"I can see stem cells replacing drugs to improve many diseases," said Gerson. "Stem cells can replace injured cells, improve the function of many organs in the body and provide specific new functions to treat many diseases."
The Third Frontier funding will support the following commercial, emerging and pilot programs:
• Commercial programs:
The commercial projects are expected to generate significant near term value for the sponsoring companies and the State of Ohio.
Athersys and Kenneth Cooke (UHCMC and Case Western Reserve) will further evaluate MultiStem® to cure immunological reactions to cell related therapies for cancer. The goal of this project is to advance the commercialization of MultiStem® cell therapy by running a FDA approved Phase II clinical trial to evaluate the performance of the cells.
Juventas Therapeutics, spin out company from Marc Penn (CC), will develop its lead drug product, stromal cell derived factor 1 (SDF-1), through a Phase I clinical trial for critical limb ischemia.
• Emerging programs:
With further refinement of already established proof of concept, the following programs could mature into significant opportunities for CSCRM and the region.
Gerson is partnering with Lentigen, Inc, of Gaithersburg, Md., to develop a gene therapy approach to treating brain tumors.
Jean Welter (Case Western Reserve) and Adam Lambert (Oakwood Laboratories) are teaming up to develop a combination product comprised of a drug and Oakwood's proprietary sustained release technology to treat arthritic disease.
Eben Alsberg (Case Western Reserve) and Orthopediatrics of Warsaw, Ind., will use microspheres tuned to release a specific amount of drug over a prolonged period of time to tell the patient's cells to create cartilage.
Bruce Trapp (CC) and Vertex Pharmaceuticals of Cambridge, Mass., have identified a cell in the adult human brain and will evaluate its potential to treat a variety of neurodegenerative diseases and spinal cord injury.
• Pilot programs:
The pilot projects represent early stage, cutting edge scientific projects that were developed in the Center. While these projects are at an early stage, they were selected based upon their significance to the field and their potential economic impact if successfully matured. Funding for the three projects will be accompanied by a subset of eight new pilot projects determined through review by CSCRM oversight committees.
Paul Tesar (Case Western Reserve), Horst von Recum (Case Western Reserve) and Jeremy Rich (CC) will establish a Pluripotent Stem Cell Facility within Case Western Reserve and CC which will be the first of its kind in the State of Ohio.
Cell Targeting will apply its cell "painting" technology to direct umbilical cord blood stem cells to specific locations in the body to increase cell dosage and improve engraftment.
Zhenghong Lee (UHCMC) and Jeremy Rich (CC) will collaborate to develop a method to non-invasively image cancer stem cells through the development of radiolabeled tracers.
The CSCRM Administration, led by Debra Grega and Michael Gilkey, is responsible for coordinating, accounting and reporting on all of these projects, continuing and creating education programs on stem cells and regenerative medicine for middle school through graduate level students, executing a biennial international stem cell conference (MSC 2009), interfacing and cultivating new commercial interactions, developing new research collaborations within the State as well as internationally, and representing the Center in scientific conferences and public events.
The funding will help support new stem cell technologies including two commercial, four emerging and three pilot projects. This funding will be matched by each of the projects to create a $10 million grant benefiting stem cell and regenerative medicine in Ohio.
"This funding provides CSCRM the support it needs to continue to aggressively move new technologies from academic labs towards commercial development," said Stan Gerson, director of the Center for Stem Cell & Regenerative Medicine. "We have linked corporate partners to our major projects and have been gratified by the development of a stem cell biotechnology commercial landscape in our region. Our goal is to rapidly move stem cell research from the lab to patients through clinical trials, using our strong background in preclinical models."
The continued research efforts will result in efficient clinical applications and commercialization of stem cells to benefit patients throughout Ohio. To date, such efforts have brought in $170 million in new commercial development and investment in Ohio.
"This grant continues to build distinctive and broad reach capabilities that are making Ohio a leader in the development and clinical use of cellular therapies," said Baiju R. Shah, President and CEO of BioEnterprise. "Ohioans benefit both through the resulting company development and jobs as well as by having access to leading-edge clinical therapies at our region's clinical institutions."
The use of stem cells has focused on leukemia and myeloma treatments with recent applications in cardiovascular disease. Current healthcare is limited to the use of drugs or devices to treat disease and injury. CSCRM, located in Northeast Ohio but collaborating state wide, is positioned to implement new stem cell technologies in the commercial and therapeutic arenas.
"I can see stem cells replacing drugs to improve many diseases," said Gerson. "Stem cells can replace injured cells, improve the function of many organs in the body and provide specific new functions to treat many diseases."
The Third Frontier funding will support the following commercial, emerging and pilot programs:
• Commercial programs:
The commercial projects are expected to generate significant near term value for the sponsoring companies and the State of Ohio.
Athersys and Kenneth Cooke (UHCMC and Case Western Reserve) will further evaluate MultiStem® to cure immunological reactions to cell related therapies for cancer. The goal of this project is to advance the commercialization of MultiStem® cell therapy by running a FDA approved Phase II clinical trial to evaluate the performance of the cells.
Juventas Therapeutics, spin out company from Marc Penn (CC), will develop its lead drug product, stromal cell derived factor 1 (SDF-1), through a Phase I clinical trial for critical limb ischemia.
• Emerging programs:
With further refinement of already established proof of concept, the following programs could mature into significant opportunities for CSCRM and the region.
Gerson is partnering with Lentigen, Inc, of Gaithersburg, Md., to develop a gene therapy approach to treating brain tumors.
Jean Welter (Case Western Reserve) and Adam Lambert (Oakwood Laboratories) are teaming up to develop a combination product comprised of a drug and Oakwood's proprietary sustained release technology to treat arthritic disease.
Eben Alsberg (Case Western Reserve) and Orthopediatrics of Warsaw, Ind., will use microspheres tuned to release a specific amount of drug over a prolonged period of time to tell the patient's cells to create cartilage.
Bruce Trapp (CC) and Vertex Pharmaceuticals of Cambridge, Mass., have identified a cell in the adult human brain and will evaluate its potential to treat a variety of neurodegenerative diseases and spinal cord injury.
• Pilot programs:
The pilot projects represent early stage, cutting edge scientific projects that were developed in the Center. While these projects are at an early stage, they were selected based upon their significance to the field and their potential economic impact if successfully matured. Funding for the three projects will be accompanied by a subset of eight new pilot projects determined through review by CSCRM oversight committees.
Paul Tesar (Case Western Reserve), Horst von Recum (Case Western Reserve) and Jeremy Rich (CC) will establish a Pluripotent Stem Cell Facility within Case Western Reserve and CC which will be the first of its kind in the State of Ohio.
Cell Targeting will apply its cell "painting" technology to direct umbilical cord blood stem cells to specific locations in the body to increase cell dosage and improve engraftment.
Zhenghong Lee (UHCMC) and Jeremy Rich (CC) will collaborate to develop a method to non-invasively image cancer stem cells through the development of radiolabeled tracers.
The CSCRM Administration, led by Debra Grega and Michael Gilkey, is responsible for coordinating, accounting and reporting on all of these projects, continuing and creating education programs on stem cells and regenerative medicine for middle school through graduate level students, executing a biennial international stem cell conference (MSC 2009), interfacing and cultivating new commercial interactions, developing new research collaborations within the State as well as internationally, and representing the Center in scientific conferences and public events.
